Recently approved treatments for spinal muscular atrophy (SMA) may shift clinical care priorities to secondary complications associated with SMA-related aging. To date, there is little knowledge about the natural history of morbidities across the adult lifespan for SMA. The objective of this study was to identify the risk of various morbidities among adults with vs. without SMA prior to SMA-related treatment.
No takes yet. Share an insight, caveat, or question.
G et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: